当前位置：
X-MOL 学术
›
Lancet Diabetes Endocrinol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
GLP-1 receptor agonists: differentiation within the class.
The Lancet Diabetes & Endocrinology ( IF 44.0 ) Pub Date : 2017-12-06 , DOI: 10.1016/s2213-8587(17)30413-8 Simeon I Taylor 1
Glucagon-like peptide 1 (GLP-1) functions as an incretin, which promotes insulin secretion in response to oral glucose. Several pharmaceutical companies have developed GLP-1 receptor agonists, including five approved to treat type 2 diabetes, or both type 2 diabetes and obesity. These drugs provide several therapeutic benefits, including improved glycaemic control and weight loss.
中文翻译：
GLP-1 受体激动剂：类别内的分化。
胰高血糖素样肽 1 (GLP-1) 起到肠促胰岛素的作用，可响应口服葡萄糖促进胰岛素分泌。多家制药公司已开发出 GLP-1 受体激动剂，其中五种已获批准用于治疗 2 型糖尿病，或同时治疗 2 型糖尿病和肥胖症。这些药物提供多种治疗益处，包括改善血糖控制和减轻体重。
更新日期：2018-01-24
The Lancet Diabetes & Endocrinology ( IF 44.0 ) Pub Date : 2017-12-06 , DOI: 10.1016/s2213-8587(17)30413-8 Simeon I Taylor 1
Affiliation
|
Glucagon-like peptide 1 (GLP-1) functions as an incretin, which promotes insulin secretion in response to oral glucose. Several pharmaceutical companies have developed GLP-1 receptor agonists, including five approved to treat type 2 diabetes, or both type 2 diabetes and obesity. These drugs provide several therapeutic benefits, including improved glycaemic control and weight loss.
中文翻译：
GLP-1 受体激动剂：类别内的分化。
胰高血糖素样肽 1 (GLP-1) 起到肠促胰岛素的作用，可响应口服葡萄糖促进胰岛素分泌。多家制药公司已开发出 GLP-1 受体激动剂，其中五种已获批准用于治疗 2 型糖尿病，或同时治疗 2 型糖尿病和肥胖症。这些药物提供多种治疗益处，包括改善血糖控制和减轻体重。
京公网安备 11010802027423号